|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2400094032 |
|
最近更新日期: Date of Last Refreshed on: |
2024-12-16 15:37:25 |
|
注册时间: Date of Registration: |
2024-12-16 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
基于肠道微生态多组学的阻塞性睡眠呼吸暂停研究 |
|
Public title: |
obstructive sleep apnea(OSA) research based on multi-omics of intestinal microecology |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
基于肠道微生态多组学的阻塞性睡眠呼吸暂停发病机制与干预新策略研究 |
|
Scientific title: |
The pathogenesis and intervention research of obstructive sleep apnea(OSA) based on multi-omics of intestinal microecology |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
周爱娜 |
研究负责人: |
陈雄 |
|
Applicant: |
Zhou Aina |
Study leader: |
Chen Xiong |
|
申请注册联系人电话: Applicant telephone: |
+86 130 3713 1962 |
研究负责人电话:
Study leader's |
+86 139 9559 9373 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
ZAN641922@163.COM |
研究负责人电子邮件: Study leader's E-mail: |
47102470@qq.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
中国湖北省武汉市东湖路115号武汉大学医学部 |
研究负责人通讯地址: |
中国湖北省武汉市东湖路125号武汉大学中南医院 |
|
Applicant address: |
Faculty of Medical Sciences of Wuhan University, 115 Donghu Road, Wuhan, Hubei, China |
Study leader's address: |
Zhongnan Hospital of Wuhan University,125 Donghu Road, Wuhan, Hubei, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
武汉大学第二临床学院(武汉大学中南医院) |
||
|
Applicant's institution: |
Second Clinical Hospital of Wuhan University (Zhongnan Hospital of Wuhan University) |
||
|
研究负责人所在单位: |
武汉大学中南医院 |
||
|
Affiliation of the Leader: |
Zhongnan Hospital of Wuhan University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
临研伦[2024060] |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
武汉大学中南医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Committee Zhongnan Hospital of Wuhan University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-03-27 00:00:00 | ||
|
伦理委员会联系人: |
胡梦薇 |
||
|
Contact Name of the ethic committee: |
Hu Mengwei |
||
|
伦理委员会联系地址: |
湖北省武汉市武昌区东湖路169号门诊楼11楼 |
||
|
Contact Address of the ethic committee: |
Outpatient buildinng,11 floor, No.169 Donghu Road, Wuchang DIstrict, Wuhan, Hubei, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 27 6781 2787 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
武汉大学中南医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Zhongnan Hospital of Wuhan University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
武汉大学中南医院 |
||||||||||||||||||||||
|
Primary sponsor's address: |
Zhongnan Hospital of Wuhan University |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
湖北省重点研发计划项目 |
||||||||||||||||||||||
|
Source(s) of funding: |
Key Research and Development Program of Hubei Province |
||||||||||||||||||||||
|
研究疾病: |
阻塞性睡眠呼吸暂停 |
||||||||||||||||||||||
|
Target disease: |
obstructive sleep apnea(OSA) |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
病例对照研究 |
||||||||||||||||||||||
|
Study design: |
Case-Control study |
||||||||||||||||||||||
|
研究目的: |
1.利用粪便宏基因组和血清代谢组学数据构建阻塞性睡眠呼吸暂停疾病综合评估模型,包括风险预测、疾病精准分型和预后评估。 2. 找寻阻塞性睡眠呼吸暂停疾病相关关键肠道菌群行机制研究,探索因果关系,并以此开发新的临床治疗模式。 |
||||||||||||||||||||||
|
Objectives of Study: |
1. Construct a comprehensive disease assessment model for obstructive sleep apnea using fecal metagenomic and serum metabolomics data, including risk prediction, accurate disease classification, and prognosis assessment. 2. Explore the mechanism of OSA-related key gut microbiota, explore the causal relationship, and develop new clinical treatment models. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
年龄18-65 岁,饮食规律 。 根据指南诊断为阻塞性睡眠呼吸暂停疾病者纳入病例组,无阻塞性睡眠呼吸暂停等睡眠呼吸障碍疾病者纳入健康对照。 |
||||||||||||||||||||||
|
Inclusion criteria |
Age: 18-65 years, regular diet. Patients diagnosed as obstructive sleep apnea disease according to the guidelines were included in the case group, and healthy controls without obstructive sleep apnea and other sleep breathing disorders were included in the control group. |
||||||||||||||||||||||
|
排除标准: |
①近一年内有创伤、手术和严重感染者,既往有颅脑外伤、神经、精神病、血液系统疾病史;②严重肝肾功能不全;③患恶性肿瘤,甲状腺、肾上腺等全身性疾病者;④有自身免疫性疾病病史;⑤患有影响肠道菌群如慢性胃炎、胃溃疡等胃肠道疾病者; ⑥1月内抗生素或长期中药服用史;1周内肠镜检测,肠道灌肠,服用益生菌、益生元或饮酒。⑦以往OSA治疗史。 |
||||||||||||||||||||||
|
Exclusion criteria: |
(1) Subjects with trauma, surgery or severe infection within the past year, and with previous history of craniocerebral trauma, neurological, psychiatric or hematological diseases; (2) Subjects with severe hepatic and renal insufficiency; (3) Subjects with malignant tumors, thyroid, adrenal and other systemic diseases; (4) Subjects with the history of autoimmune diseases; (5) Subjects with gastrointestinal diseases affecting intestinal microorganism such as chronic gastritis and gastric ulcer; (6) Subjects who taking antibiotics, traditional Chinese medicine within 1 month or taking probiotics, prebiotics or drinking within 1 week; subjects who suffering colonoscopy or intestinal enema within 1 week. (7)Subjects with previous treatment involved in OSA. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2024-04-01 00:00:00至 To 2026-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2024-04-01 00:00:00 至 To 2026-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
无 |
|
Blinding: |
None |
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
国家生物信息中心 (https://ngdc.cncb.ac.cn/gsub/) |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
China National center for Bioinformation (https://ngdc.cncb.ac.cn/gsub/) |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
1.病历记录表采集数据 2.武汉大学中南医院自行开发的“睡眠障碍信息管理系统”进行数据管理 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
1.Data are collected on a case record form 2.Sleep disorder information management system developed by Zhongnan Hospital of Wuhan University is used for data management. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |